Drug Profile

Research programme: SARS-CoV-2 papain like protease inhibitors - Clear Creek Bio

Alternative Names: SARS-CoV-2 PLpro inhibitors - Clear Creek Bio

Latest Information Update: 18 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

11 Jan 2022 SARS-CoV-2 papain-like protease inhibitors is available for licensing as of 11 Jan 2022. (Clear Creek Bio website, January 2022)
06 Jan 2022 Clear Creek Bio enteres into a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) for SARS-CoV-2 papain-like protease (PLpro) inhibitor in COVID-2019 infections
06 Jan 2022 Early research in COVID-2019 infections in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com